Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of macular edema associated with non-infectious uveitis using Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal (SCS) injection using Clearside’s proprietary microinjector.
29 December 2014
2014: Reading Between the Lines
William Looney, Pharmaceutical Executive
The calendar say it's wrap up time, not just for gifts, but for some of the trends that shaped big Pharma—for good or bad—during the past year. A simple way to close the book on 2014 is to draw some insights from our three feature stories this month. Whether by design or circumstance, our efforts reveal the random diversity of threats and opportunities facing the industry today.
29 December 2014
Janssen Pharmaceuticals R&D Adopts A Venture Capital Innovation Model
Fred Olds, Life Sciences Leader
Faced with diminishing returns on R&D investments, large pharmaceutical companies are searching for innovative ways to successfully identify, develop, and market products with financial viability. Yet small discovery companies and biotechs continue to outpace large pharma in the approval of NMEs (new molecular entities).
26 December 2014
Get ready to negotiate, drugmakers: Payers are armed for drug-pricing battle
Tracy Staton, FiercePharma
If 2014 was the year of the emboldened U.S. payer, then 2015 promises to be the year of the pharma negotiator.
25 December 2014
Limited attention span? Focus on these market shake-ups in 2015
Emily Wasserman, FiercePharma
It has been a whirlwind of a year for pharma, with pricing battles, regulatory showdowns and all-but-legendary M&A. And on the ground, it's Rock-em-Sock-em Robots in some of the industry's biggest markets. A steady flow of new drugs in 2014--and a slate of anticipated launches in 2015--have established brands defending their titles and newcomers looking to land a gut-punch or two, if not a knockout. Here are the match-ups to watch in the coming year. Think we missed something? As always, let us know.
25 December 2014
Continuous manufacturing reaches a turning point
Eric Palmer, FeircePharmaManufactoring
For years drug companies have been talking about continuous manufacturing, a drugmaking process that is cheaper, faster, easier on the environment, requires smaller facilities, and can be ramped up quickly in remote locations. Did we mention cheaper?
25 December 2014
Will biopharma keep riding that mammoth M&A wave? Short answer's yes
Carly Helfand, FiercePharma
It's been a wild ride through the M&A world for pharma this year, and analysts predict that may just continue into 2015. Companies have been wheeling and dealing at breakneck pace, with more than a couple inking multiple pacts. But plenty of drugmakers are still in search of a deal that will move the needle.
24 December 2014
Russia and neighboring Belarus step up cooperation in R&D
MarchMont Innovation News
Next year may see the launch of 17 large-scale Russo-Belarusian projects in applied sciences, Belarusian portal Naviny.by reported, citing Alexander Shumilin, the chairman of Belarus’ State Committee for Science and Technology. According to the government official, these are projects in areas such as biotechnology, medicine, space research, information and telecommunications technologies, new materials, nanotechnology, and laser technology.
24 December 2014
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
Laurie Kulikowski, TheStreet
Which biotech and pharmaceuticals stocks should investors buy in 2015? J.P. Morgan analysts named six "Pharmaceuticals, Biotechnology" companies with the best investment cases as part of its top U.S. stocks picks for 2015. The overall stock picks list includes 48 companies across sectors and strategy focus. The firm only chose companies with at least $5 million in average daily trading volume.
24 December 2014
Best and worst 2014 biotech performers on Wall Street
Stacy Lawrence, FierceBiotech
A little profit-taking in biotech into year end is only to be expected from Wall Street after such a strong year. Some of the most likely victims for a bit of bloodletting are the strongest winners. Or these companies might be able to keep up their momentum on the back of biotech excitement going into the definitive industry extravaganza, the J.P. Morgan Healthcare conference in mid-January.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.